Royalty Pharma (RPRX) Q4 FY25 earnings call

Royalty Pharma delivered a landmark Q4 FY25, marked by robust double-digit growth in portfolio and royalty receipts, driven by its diversified asset base. The company significantly outpaced its capital deployment targets, achieving its 5-year goal a year early, while also internalizing its management for improved efficiency. Management remains confident in its long-term growth trajectory and ability to generate substantial shareholder value through strategic capital allocation and a resilient pipeline.